|Day's Range||5.80 - 5.93|
BRIDGEWATER, N.J., Nov. 13, 2019 /PRNewswire/ -- Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TXS: BHC), in collaboration with TerraCycle®, a world leader in the collection and repurposing of hard-to-recycle post-consumer waste, today announces the donation of custom training modules to the Guide Dog Foundation, a national not-for-profit that trains guide dogs for people who are blind or visually impaired. The training modules, including benches, tables, waste stations and an agility ramp, were made from used contact lens materials collected through the Bausch + Lomb ONE by ONE Recycling Program, the first and only contact lens recycling program of its kind in the United States, along with other recycled material.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Bausch Health Companies Inc (NYSE: BHC ) reported Monday ahead of the market open with better-than-expected third-quarter revenue and higher non-GAAP earnings. The company also raised its fiscal year 2019 ...
Shares of Bausch Health , formerly known as Valeant, rose Monday after third-quarter revenue exceeded expectations, and the pharmaceutical company increased its revenue guidance. Bausch Health, based in Laval, Canada, reported a loss of $49 million, or 14 cents a share, in the latest quarter, shrinking from a loss of $350 million, or $1 a share, a year ago.
Bausch (BHC) delivered earnings and revenue surprises of 12.26% and 2.54%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Bausch Health Cos. Inc. said Monday it had a met loss of $49 million, or 14 cents a share, in the third quarter, after a loss of $350 million, or $1.00 a share, in the year-earlier period. Adjusted net income came to $425 million, the company said. It did not provide an adjusted per-share number. The FactSet consensus was for EPS of $1.09. Revenue rose to $2.209 billion from $2.136 billion, compared with a FactSet consensus of $2.155 billion. The company, which was formerly called Valeant, said revenue at its Bausch & Lomb/International segment rose 2% to $1.175 billion. Revenue at its Salix segment rose 20% to $551 million, revenue at ortho dermatologics fell 16% to $147 million, while revenue from diversified products fell 5% to $336 million. The company is now expecting full-year revenue of $8.475 billion to $8.625 billion, compared with prior guidance of 8.40 billion to $8.60 billion, Shares rose 3.4% in premarket trade and have gained 40% in 2019, while the S&P 500 has gained 22%.
Bausch Health Companies Inc. Announces Third-Quarter 2019 Results and Raises Full-Year Revenue and Adjusted EBITDA (non-GAAP) Guidance Ranges
Bausch Health Companies (NYSE: BHC ) announces its next round of earnings this Monday, November 4. Here is Benzinga's everything-that-matters guide for this Monday's Q3 earnings announcement. Earnings ...
A U.S. appeals court on Thursday upheld the convictions of two drug industry executives for defrauding Valeant Pharmaceuticals International Inc through a multimillion-dollar kickback scheme, but reduced how much they must forfeit for their crimes. The 2nd U.S. Circuit Court of Appeals in Manhattan rejected arguments by Gary Tanner, a former Valeant executive, and Andrew Davenport, a former chief executive of mail order pharmacy Philidor Rx Services LLC, that the evidence did not support their convictions, and that the jury instructions were defective. It also said Preska abused her discretion by ordering $8 million in restitution to Valeant, now known as Bausch Health Cos, and told her to find a "sound methodology" to assess the Canadian company's losses.
BRIDGEWATER, N.J., Oct. 30, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) and its gastroenterology business, Salix Pharmaceuticals ("Salix"), one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal (GI) diseases, today announced the start of the applications period for its inaugural Salix Gastrointestinal Health Scholars Program, which will award a total of $100,000 in scholarships to ten outstanding students living with GI disease who are pursuing their higher education goals. "At Salix, we are dedicated to continuous innovation in order to address the unmet needs of patients.
Ahead of World Psoriasis Day, Bausch Health, Canada announces that SILIQ® (brodalumab) is now covered on most drug benefit formularies in Canada
Bausch (BHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Salix Pharmaceuticals to Present New Clinical Data at the American College of Gastroenterology (ACG) Annual Meeting